kchip2  (Alomone Labs)

Journal: Scientific Reports

Article Title: The Kv4 potassium channel modulator NS5806 attenuates cardiac hypertrophy in vivo and in vitro

doi: 10.1038/s41598-024-70962-x

Figure Lengend Snippet: Effects of NS5806 on I to channel-related gene and protein expression. ( A – C ) Quantification of the mRNA levels of Kv4.2 ( A ), KChIP2 ( B ) and DPP6 ( C ). GAPDH served as an internal control (n = 9 in each group). ( D ) Representative immunoblots. Original blots are presented in Supplementary Figure . ( E – G ) Summary data of Kv4.2 ( E ), KChIP2 ( F ) and DPP6 ( G ) protein levels. GAPDH served as an internal control (n = 5 in each group). * P < 0.05, ** P < 0.01 versus the Sham + Vehicle group. # P < 0.05, ## P < 0.01 versus TAC + Vehicle.

Article Snippet: Primary antibodies against Kv4.2 (1:500, 75–016, NeuroMab, USA), KChIP2 (1:500, DF14620, Affinity, China), DPP6 (1:200, APC-146, Alomone, Israel) and GAPDH (1:10,000, 10494-1-AP, Proteintech, China) were incubated at 4 °C overnight.

Techniques: Expressing, Control, Western Blot

Journal: Cells

Article Title: Influence of Age on Hyperoxia-Induced Cardiac Pathophysiology in Type 1 Diabetes Mellitus (T1DM) Mouse Model

doi: 10.3390/cells12111457

Figure Lengend Snippet: Protein profiles of key potassium channels and sex hormone receptors in hearts of aged Akita mice. Key potassium channels and their auxiliary proteins such as KChIP2, Kv1.4, Kv1.5, and Kv4.2 and housekeeping gene GAPDH ( a ), and androgen receptor (AR) and estrogen receptors (ER-α and β) ( b ). Values shown in the tables are mean (±SE) normalized band intensities from n = 4 per group. * represents p < 0.05 and ** p < 0.005 between normoxia and hyperoxia.

Article Snippet: Blots were later blocked in 5% w / v nonfat dry milk for 1 h and probed in 1:5000 dilutions of primary antibodies for Kv1.4 (AB5926) and GAPDH (Millipore) antibodies, and 1:1000 dilutions of KChIP2 (Abcam, Cambridge, MA, USA), Kv4.2 (Millipore, Billerica, MA, USA), estrogen receptor beta (Thermo Fisher, CA, USA), androgen receptor (Abcam, Cambridge, MA, USA), and Kv1.5 antibody (Santa Cruz Biotechnology, Dallas, TX, USA).

Techniques: